Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 8/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.48 |
| ▸ | CCR5 | P51681 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylphenylsulfone SCHEMBL6169663 | 0.91 | PTGER1 (0.52) | PTGER1KMT2ALRRK2CYP2C9 | |
| SCHEMBL6193635 | 0.90 | MAOB (0.51) | PTGER1KMT2ACYP2C9MRGPRX4 | |
| SCHEMBL5627922 | 0.88 | PTGER1 (0.55) | PTGER1KMT2ALRRK2CYP2C9MRGPRX4 | |
| SCHEMBL5474984 | 0.88 | CCR5 (0.53) | PTGER1LRRK2CYP2C9MRGPRX4CCR5 | |
| SCHEMBL5627949 | 0.86 | MRGPRX4 (0.48) | PTGER1KMT2AMRGPRX4CCR5 | |
| SCHEMBL4722050 | 0.85 | PTGER1 (0.64) | PTGER1KMT2ALRRK2CYP2C9MRGPRX4 | |
| SCHEMBL29836110 | 0.85 | PTGER1 (0.64) | PTGER1KMT2ALRRK2CYP2C9MRGPRX4 | |
| SCHEMBL5627324 | 0.85 | LRRK2 (0.56) | PTGER1LRRK2CCR5 | |
| SCHEMBL8569688 | 0.85 | PTGER1 (0.57) | PTGER1KMT2ALRRK2CYP2C9MRGPRX4 | |
| SCHEMBL5627323 | 0.84 | SGMS2 (0.55) | PTGER1KMT2ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070082912-A1 | Pyrrole compounds for the treatment of prostaglandine mediated diseases | GLAXO GROUP LIMITED (GB) | 2007-04-12 | — | — | US | disclosed |
| US-20070082912-A1 | Pyrrole compounds for the treatment of prostaglandine mediated diseases | GLAXO GROUP LIMITED (GB) | 2007-04-12 | — | — | US | disclosed |
| US-20070082912-A1 | Pyrrole compounds for the treatment of prostaglandine mediated diseases | GLAXO GROUP LIMITED (GB) | 2007-04-12 | — | — | US | disclosed |
| US-20070072906-A1 | Pyrrole compounds | GLAXO GROUP LIMITED (GB) | 2007-03-29 | — | — | US | disclosed |
| US-20070072906-A1 | Pyrrole compounds | GLAXO GROUP LIMITED (GB) | 2007-03-29 | — | — | US | disclosed |
| US-20070072906-A1 | Pyrrole compounds | GLAXO GROUP LIMITED (GB) | 2007-03-29 | — | — | US | disclosed |
| EP-1697319-A1 | PYRROLE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005054191-A1 | PYRROLE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-06-16 | — | — | WO | disclosed |
| EP-1509499-A1 | PYRROLE COMPOUNDS FOR THE TREATMENT OF PROSTAGLANDIN MEDIATED DISEASES | GLAXO GROUP LIMITED (GB) | 2005-03-02 | — | — | EP | disclosed |
| WO-2003101959-A1 | PYRROLE COMPOUNDS FOR THE TREATMENT OF PROSTAGLANDIN MEDIATED DISEASES | GLAXO GROUP LIMITED (GB) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072906-A1 | Pyrrole compounds | PRMT9, EPOR, ADCYAP1R1 | PTGER1 224/4885KMT2A 1834/4885LRRK2 1070/4885 |
| US-20070082912-A1 | Pyrrole compounds for the treatment of prostaglandine mediated diseases | PTGER1, PTGDR, PTGIR | PTGER1 1/4885KMT2A 2989/4885LRRK2 1908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.